首页> 中文期刊>世界中医药 >复方苦参肠溶胶囊与谷氨酰胺肠溶胶囊联合美沙拉嗪治疗溃疡性结肠炎的疗效比较

复方苦参肠溶胶囊与谷氨酰胺肠溶胶囊联合美沙拉嗪治疗溃疡性结肠炎的疗效比较

     

摘要

目的:比较复方苦参肠溶胶囊与谷氨酰胺肠溶胶囊分别联合美沙拉嗪治疗溃疡性结肠炎的临床疗效.方法:选取2012年1月至2015年12月我院收治的80例溃疡性结肠炎患者,随机将患者分为复方苦参肠溶胶囊联合美沙拉嗪组(A组,n =40)和谷氨酰胺肠溶胶囊联合美沙拉嗪组(B组,n=40).比较2组患者的临床疗效、临床症状改善时间(退热时间、止泻时间、症状体征消失时间)、血清中红细胞沉降率(ESR)、血清中C反应蛋白(CRP)、血清中IL-8与IL-10表达水平、不良反应发生情况及复发情况.结果:B组患者治疗有效率(97.5%)显著高于A组患者(87.5%)(P<0.05);B组患者的止泻时间、退热时间及症状体征消失时间均短于A组患者(P<0.05);2组患者C反应蛋白、血细胞沉降率差异无统计学意义(P>0.05);用药后2组血清中IL-8与IL-10表达水平变化差异极显著,用药后B组较A组血清中IL-8、IL-10水平差异有统计学意义(P<0.05);B组患者不良反应发生率显著低于A组(P<0.05).结论:复方谷氨酰胺肠溶胶囊联合美沙拉嗪治疗溃疡性结肠炎能够显著提高临床治疗效果,改善临床症状,且不良反应率低,值得临床推广.%Objective:To compare the effectiveness of compound sophora enteric capsules and glutamine enteric capsules combined with mesalazine in the treatment of ulcerative colitis.Methods:A total of 80 cases of patients with ulcerative colitis came to our hospital from January 2012 to December 2012 were randomly divided into a group A and a group B.Group A was treated with mesalazine combined with compound sophora enteric capsules,and group B was treated with Glutamine compound enteric capsules combined with mesalazine.The clinical curative effect,clinical symptoms improved time,ESR,CRP,the serum IL-8 and IL-10 levels,recurrence and adverse reactions were compared between two groups.Results:The treatment efficiency (97.5 %) of group B was significantly higher than that of group A (87.5%) (P < 0.05).Diarrhea time,cooling time,and symptoms and signs disappeared of group B were shorter than those of group A (P < 0.05).The differences of the data about C-reactive protein,blood cell sedimentation rate between two groups had no statistically significant (P > 0.05).After treatment IL-8 and IL-10 level in the two groups changed significantly,group B significantly lower than group A (P < 0.05).Incidence of adverse reactions of group B was significantly lower than that of group A (P < 0.05).Conclusion:Glutamine compound enteric capsules combined with mesalazine can significantly improve clinical outcomes and clinical symptoms,and decrease adverse reaction rate in ulcerative colitis patients,which was worthy of promotion.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号